Conduction Defect
8
1
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
15 treatments under study, led by Atacor Stealthtrac Lead
Related Conditions
Often studied with 20 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (8)
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
Pilot evaluatIon Of NovEl tEmpoRary ExtraVascular PACING (PIONEER EV PACING) Study
Subcostal Temporary Extravascular Pacing V Study
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
Subcostal Temporary Extravascular Pacing IV (STEP IV) Study
AtaCor Subcostal Temporary Extravascular Pacing III Study
Subcostal Temporary Extracardiac Pacing II Study
Subcostal Temporary Extracardiac Pacing Study
Research Network
Common Treatments
- Atacor Stealthtrac Lead4
- Stealthtrac Lead Only Control1
- Subprotocol F1
- Subprotocol B1
- Subprotocol H1
Active Sponsors
- AtaCor Medical, Inc.6
- Peerbridge Health, Inc2
Top Investigators
AtaCor Medical, Inc.
Peerbridge Health, Inc
Sanatorio Italiano
AtaCor Medical
Hackensack Meridian Health
Related Conditions
- Hfref Heart Failure With Reduced Ejection Fraction2
- Syncope2
- Lv Dysfunction2
- Lvf2
- Atrial Enlargement2